Obesity and insulin resistance: Pathophysiology and treatment.

Abstract

The prevalence of obesity is a major cause of many chronic metabolic disorders, including type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD), and cancer. Insulin resistance is often associated with metabolic unhealthy obesity (MUO). Therapeutic approaches aiming to improve insulin sensitivity are believed to be central for the prevention and treatment of MUO. However, current antiobesity drugs are reported as multitargeted and their insulin-sensitizing effects remain unclear. In this review, we discuss current understanding of the mechanisms of insulin resistance from the aspects of endocrine disturbance, inflammation, oxidative, and endoplasmic reticulum stress (ERS). We then summarize the antiobesity drugs, focusing on their effects on insulin sensitivity. Finally, we discuss strategies for obesity treatment.

• Authors: Yue Tong, Sai Xu, Lili Huang, Chen Chen
• Journal: Drug discovery today (Drug Discov Today) Vol. 27 Issue 3 Pg. 822-830 (03 2022) ISSN: 1878-5832 [Electronic] England
• PMID: 34767960 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2021 Elsevier Ltd. All rights reserved.

Chemical References

• Anti-Obesity Agents
• Insulin

Topics

• Anti-Obesity Agents (therapeutic use)
• Diabetes Mellitus, Type 2 (drug therapy)
• Humans
• Insulin (metabolism)
• Insulin Resistance
• Obesity (drug therapy, metabolism)